MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

Search

Incyte Corp

Cerrado

SectorSanidad

59.14 0.37

Resumen

Variación precio

24h

Actual

Mínimo

58.68

Máximo

59.17

Métricas clave

By Trading Economics

Ingresos

95M

201M

Ventas

39M

1.2B

P/B

Media del Sector

378.667

57.333

BPA

1.43

Margen de beneficios

17.071

Empleados

2,617

EBITDA

145M

337M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+24.86% upside

Dividendos

By Dow Jones

Próximas Ganancias

29 abr 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-5.4B

11B

Apertura anterior

58.77

Cierre anterior

59.14

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

Incyte Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

25 abr 2025, 17:01 UTC

Ganancias
Principales Movimientos del Mercado

Aon Shares Sink After 1Q Profit Falls, Sales Miss Estimates

25 abr 2025, 16:10 UTC

Ganancias
Principales Movimientos del Mercado

Coursera Shares Rise After 1Q Beat, Better-Than-Expected Revenue View

26 abr 2025, 15:00 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Trump 2.0 Era Brings Flurry of Crypto Deals -- WSJ

26 abr 2025, 11:00 UTC

Principales Noticias

America's Leather Economy Has Gone Global, and Now It Can't Escape the Trade War -- WSJ

26 abr 2025, 08:20 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

26 abr 2025, 03:00 UTC

Principales Noticias

The Chinese Satellite Firm Washington Accuses of Helping U.S. Foes -- WSJ

25 abr 2025, 21:24 UTC

Principales Noticias

Cargo Shipments From China to the U.S. Dwindle -- WSJ

25 abr 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

25 abr 2025, 20:45 UTC

Principales Noticias

Stocks Claw Back Most of April's Tariff Losses -- WSJ

25 abr 2025, 20:39 UTC

Ganancias

The Score: Tesla, Capital One, Boeing and More Stocks That Defined the Week -- WSJ

25 abr 2025, 20:37 UTC

Principales Noticias

Trump Administration Lays Out Tariff Roadmap to Streamline Trade Talks -- WSJ

25 abr 2025, 20:19 UTC

Principales Noticias

Nasdaq Climbs More Than 1% as Stocks Finish Strong Week -- WSJ

25 abr 2025, 20:15 UTC

Ganancias

Week's Best: A Dividend Expert's Best Advice -- Barrons.com

25 abr 2025, 19:23 UTC

Charlas de Mercado

U.S. Natural Gas Futures Extend Weekly Losses -- Market Talk

25 abr 2025, 19:18 UTC

Charlas de Mercado

Oil Futures End Choppy Week With Losses -- Market Talk

25 abr 2025, 18:47 UTC

Charlas de Mercado

Gold Extends Pullback to Close Week -- Market Talk

25 abr 2025, 18:39 UTC

Principales Noticias

Nasdaq, Dow Industrials About Flat; Analysts Caution on Trump Tariffs -- WSJ

25 abr 2025, 18:34 UTC

Adquisiciones, fusiones, absorciones

Goldman Sachs Upgrades Schwab Stock. Here's Why. -- Barrons.com

25 abr 2025, 18:32 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

25 abr 2025, 18:32 UTC

Charlas de Mercado
Ganancias

Carriers See Tariffs Driving Up Phone Prices, Slowing Upgrades -- Market Talk

25 abr 2025, 18:08 UTC

Ganancias

Sphere Entertainment Deal Is a Win for Shareholders as Banks Take a Hit -- Barrons.com

25 abr 2025, 17:55 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises By 2 to 483 -- Market Talk

25 abr 2025, 17:40 UTC

Principales Noticias

Consumers Continue to Sour on the Economy -- 4th Update

25 abr 2025, 17:38 UTC

Ganancias

Centene Stock Falls on Medicaid Cost Worries -- Barrons.com

25 abr 2025, 17:07 UTC

Charlas de Mercado

Oil Futures Turn Higher in Quiet Trade -- Market Talk

25 abr 2025, 16:54 UTC

Charlas de Mercado
Ganancias

Mobile Carriers See Stronger Activity on Bigger Price Tags, Tariffs -- Market Talk

25 abr 2025, 16:46 UTC

Ganancias

Reddit, Meta, and Pinterest Stocks Rise. How Alphabet's Earnings Are Giving Them a Boost. -- Barrons.com

25 abr 2025, 16:20 UTC

Charlas de Mercado
Ganancias

Basic Materials Roundup: Market Talk

25 abr 2025, 16:12 UTC

Principales Noticias

Dow Industrials Fall; China Plans Economic Support During Trade Battle -- WSJ

25 abr 2025, 16:03 UTC

Ganancias

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

Comparación entre iguales

Cambio de precio

Incyte Corp previsión

Precio Objetivo

By TipRanks

24.86% repunte

Estimación a 12 Meses

Media 73.87 USD  24.86%

Máximo 92 USD

Mínimo 52 USD

De acuerdo con 18 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Incyte Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

18 ratings

6

Comprar

11

Mantener

1

Vender

Puntuación técnica

By Trading Central

57.07 / 59.22Soporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation